Concord Biotech Reports FY26 Audited Financials, Recommends Final Dividend

For the fiscal year ended March 31, 2026, Concord Biotech Limited reported a consolidated profit after tax of ₹259.23 crore.
Basic and diluted Earnings Per Share (EPS) stood at ₹24.78.

Reader Takeaway: Profitability declined year-on-year, but dividend payout and subsidiary acquisition signal growth focus.

What just happened

Concord Biotech Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a consolidated profit after tax of ₹259.23 crore on revenue from operations of ₹1,054.89 crore. Standalone profit after tax was ₹263.27 crore on revenue of ₹1,055.07 crore. The company's board has recommended a final dividend of ₹7.55 per equity share. An exceptional item of ₹3.28 crore was recognized due to the impact of new labour codes.

Why this matters

These results provide a clear picture of the company's financial performance for the full year, including profitability and earnings per share. The recommended dividend offers a direct return to shareholders, while the acquisition of a new subsidiary signals strategic expansion. An unmodified auditor opinion offers assurance on the financial reporting.

The backstory

In the previous fiscal year ended March 31, 2025, Concord Biotech had reported a consolidated profit after tax of ₹371.64 crore and revenue of ₹1,200.09 crore. The basic and diluted EPS for FY25 was ₹35.52. The company has been actively managing its corporate structure, including the recent acquisition of Celliimune Biotech Private Limited as a wholly owned subsidiary on April 2, 2026.

What changes now

Shareholders will await the approval of the final dividend, with the record date set for July 24, 2026, to determine eligibility. The newly acquired subsidiary, Celliimune Biotech Private Limited, is expected to contribute to the company's future growth. Appointments of a new independent director and auditors are also in effect.

Risks to watch

The company recognized an exceptional item of ₹3.28 crore related to new labour codes, which could impact short-term profitability. A year-on-year decline in revenue and profit requires monitoring to understand future growth drivers.

Context metrics (time-bound)

• FY26 Consolidated Revenue: ₹1,054.89 crore (down from ₹1,200.09 crore in FY25)
• FY26 Consolidated PAT: ₹259.23 crore (down from ₹371.64 crore in FY25)
• FY26 Consolidated EPS: ₹24.78 (down from ₹35.52 in FY25)
• Recommended Final Dividend: ₹7.55 per equity share
• Subsidiary Acquisition: Celliimune Biotech Private Limited (as of March 31, 2026, ₹0.012 crore invested)

What to track next

Investors should closely monitor the performance of Celliimune Biotech Private Limited and its contribution to the overall business. Further analysis of the impact of the exceptional item and the company's strategies to reverse the revenue and profit decline will be crucial.